{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-014154","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.263920+00:00","generated_at":"2026-05-27T02:27:47.536273+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"EyePoint DURAVYU Phase 2 VERONA meets primary endpoint in DME; 2.7mg shows +7.1 letter BCVA gain","bullets":["DURAVYU 2.7mg met primary endpoint with extended time to first supplemental injection vs aflibercept.","At week 24, +7.1 letter BCVA gain and 76-micron CST reduction; 73% supplement-free vs 50%.","Favorable safety: no DURAVYU-related ocular or systemic SAEs, no endophthalmitis or retinal vasculitis.","Phase 3 non-inferiority pivotal program planned by end of 2025; FDA meeting in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-014154","json":"https://secwatch.observer/filing/0000950170-25-014154.json","markdown":"https://secwatch.observer/filing/0000950170-25-014154.md","text":"https://secwatch.observer/filing/0000950170-25-014154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025014154/0000950170-25-014154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025014154/eypt-20250205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:27:47.536273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}